Ernexa Therapeutics (NASDAQ:ERNA) Posts Quarterly Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) posted its quarterly earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Ernexa Therapeutics Price Performance

Shares of ERNA stock opened at $0.32 on Friday. The firm’s 50-day moving average is $0.73 and its two-hundred day moving average is $1.12. Ernexa Therapeutics has a 12 month low of $0.27 and a 12 month high of $4.20. The company has a market capitalization of $2.54 million, a PE ratio of -0.11 and a beta of 6.58.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.